Table 3.
Estimated Incidence* of Chlamydial, Gonococcal, and Antimicrobial Resistant Gonococcal Infections in Persons Aged 15–39 years, by Sex and Age Group, United States, 2018.
| Median Number of Incident Infections† (25th–75th percentile) § |
Median Number of Incident Infections, Per 100,000 Population‡ (25th–75th percentile) § |
|||||
|---|---|---|---|---|---|---|
|
|
||||||
| Men | Women | Total|| | Men | Women | Total|| | |
|
| ||||||
| Chlamydia | ||||||
| 15–24 | 910,000 (805,000–1,026,000) | 1,728,000 (1,636,000–1,829,000) | 2,648,000 (2,506,000–2,798,000) | 4,122 (3,646–4,648) | 8,219 (7,781–8,699) | 6,144 (5,814–6,492) |
| 25–39 | 707,000 (605,000–818,000) | 625,000 (563,000–688,000) | 1,333,000 (1,213,000–1,464,000) | 2,094 (1,792–2,423) | 1,884 (1,697–2,074) | 1,992 (1,812–2,187) |
| 15–39|| | 1,621,000 (1,443,000–1,820,000) | 2,354,000 (2,236,000–2,477,000) | 3,983,000 (3,770,000–4,223,000) | 2,903 (2,584–3,260) | 4,343 (4,126–4,570) | 3,620 (3,426–3,838) |
| Gonorrhea | ||||||
| 15–24 | 277,000 (238,000–335,000) | 502,000 (426,000–595,000) | 798,000 (705,000–907,000) | 1,255 (1,078–1,517) | 2,388 (2,026–2,830) | 1,851 (1,636–2,104) |
| 25–39 | 399,000 (342,000–475,000) | 335,000 (287,000–395,000) | 750,000 (669,000–853,000) | 1,182 (1,013–1,407) | 1,010 (865–1,191) | 1,121 (1,000–1,274) |
| 15–39|| | 697,000 (618,000–796,000) | 853,000 (757,000–962,000) | 1,568,000 (1,438,000–1,722,000) | 1,248 (1,107–1,426) | 1,574 (1,397–1,775) | 1,425 (1,307–1,565) |
| Antimicrobial Resistant Gonorrhea ¶ | ||||||
| 15–24 | 142,000 (122,000–172,000) | 258,000 (219,000–305,000) | 409,000 (362,000–465,000) | 643 (553–779) | 1,227 (1,042–1,451) | 949 (840–1,079) |
| 25–39 | 205,000 (175,000–244,000) | 172,000 (147,000–203,000) | 385,000 (343,000–438,000) | 607 (518–723) | 519 (443–612) | 575 (512–654) |
| 15–39|| | 358,000 (317,000–408,000) | 438,000 (388,000–494,000) | 804,000 (738,000–883,000) | 641 (568–731) | 808 (716–911) | 731 (671–802) |
Close form solutions of ordinary differential equation-based models that assumed equilibrium and static incidence were used to estimate the incidence of both chlamydia and gonorrhea. A detailed description of these models is provided in the Mathematical Modeling Supplement.
Incidence estimates represent the cumulative number of incident infections during 2018. All counts are rounded to the nearest thousand infections. The number of incident chlamydial and gonococcal infections was calculated by multiplying the per capita incidence estimates by the American Community Survey full population estimates for 2018.
Per capita incidence estimates are represented as the number of incident infections per 100,000 population for each age-sex specific subpopulation. All numbers are rounded to the nearest full integer.
Uncertainty intervals represent the 25th and 75th percentiles of the empirical frequency distribution of a given estimate.
Total and 15–39-year-old estimates are not the sum of individual estimates, but rather descriptions of multiple distributions that have been combined.
The incidence of antimicrobial resistant gonorrhea was determined by multiplying the 2018 percentage (51.3%) of isolates from the Gonococcal Isolate Surveillance Project demonstrating resistance to ciprofloxacin, tetracycline, or penicillin, or elevated minimum inhibitory concentrations to azithromycin, ceftriaxone, or cefixime by the median gonococcal incidence estimates for 2018. (1)